Wednesday, July 8, 2026

pharma · Multiple System Atrophy · ATHE

ALTERITY THERAPEUTICS

ALTERITY THERAPEUTICS clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Melbourne, AU HQ
15 Employees
Public company Type
ATHE · NYSE Ticker
Company details
Status
Public
HQ
Melbourne, AU
Employees
15
Programs
3
Drugs
1
Patents
4
Intelligence · Clinical Programs

ALTERITY THERAPEUTICS projects

3 ClinicalTrials.gov programs sponsored by ALTERITY THERAPEUTICS.

ALTERITY THERAPEUTICS has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ATH434

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial
  2. ATH434 dose level 1

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial
  3. ATH434-DP2

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ALTERITY THERAPEUTICS have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.